Pfizer inc., Pharmaceutical company

Tokyo, April 19 Japan's Health Ministry on Tuesday approved the use of a Covid-19 vaccine developed by US pharmaceutical company Novavax to be used on people aged 18 and above.The Novavax vaccine will mark the fourth Covid inoculation approved in Japan, although will be the first protein-based vaccine compared to those developed by Pfizer and Moderna that are messenger RNA-based (mRNA) jabs, Xinhua news agency reported.The ministry hopes the Novavax jab can be administered to those who are likely to show allergic reactions to mRNA vaccines so they can still be vaccinated against the virus which is yet to be brought under control in Japan.According to Japan's public broadcaster NHK, protein-based vaccines are known to cause relatively fewer reactions, with the thinking being among the ministry that this will help the uptake of those who are as yet unvaccinated because they have been worried about side effects.The Novavax vaccine requires recipients to be jabbed twice with a three-week period between doses, the ministry said, although a third booster shot will be allowed six months or more after the second jab.Takeda Pharmaceutical will manufacture the jab locally and distribute the Novavax vaccine and is under contract to supply 150 million doses of the vaccine to the government within a year, according to official accounts.The rollout, they said, is expected to begin in late May, with Health Minister Shigeyuki Goto saying on Tuesday that the government purchased the vaccine last September to make sure Japan was in possession of a stable supply should restrictions be applied on overseas vaccines.Goto also said Novavax as a vaccine also got the green light from the government specifically because it is protein-based and is regarded as safe and effective.He added that the Japanese government had always intended to procure a variety of different vaccines so as to offer the public more choices.Local governments have been asked by the health ministry to open at least one site where the Novavax vaccine can be administered to make sure that those who prefer the protein-based jab, or require a non-mRNA for whatever reason, have access to it.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Pfizer Inc.FOLLOW

Pfizer inc., Latest News

Davos, May 25 Pfizer has announced it is to supply all its current and future patent-protected medicines and ... ...

Washington, May 24 Pfizer and its German partner BioNTech have said that preliminary clinical data showed their three-dose ... ...

New York, May 23 Pfizer on Monday announced that its third 'booster' dose was 80.3 per cent effective ... ...

Brunei reported 153 new COVID-19 cases on Friday, bringing the national tally to 142,465. ...

Tamil Nadu Health Secretary J Radhakrishnan on Thursday lauded the inauguration of a global drug development centre by the pharmaceutical company Pfizer on the Indian Institute of Technology Madras Research Park campus, and said that this would play ...

Geneva, May 5 Even as Covid drug makers are posting record profits, the lifesaving treatments often remain out ... ...

In a significant move to bring critical research and development capabilities under one roof, pharmaceutical company Pfizer has set up a global drug development centre at the IIT Madras Research Park in Tamil Nadu's Chennai. ...

Tokyo, April 19 Japan's Health Ministry on Tuesday approved the use of a Covid-19 vaccine developed by US ... ...